US4781601046
© PR Newswire
19.11.2024
JNJ
LISTED
NYSE
Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
News Preview
More than 90 presentations of clinical trial and real-world data highlight potentially practice-changing evidence and commitment to pioneer the next wave of therapies for patients with hematologic malignancies
RARITAN, N.J., Nov. 19, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from t...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
JNJ
LISTED
NYSE
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
News Preview
Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis
74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24
Comprehensive results are being prepared for presentation at upcoming...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
JNJ
LISTED
NYSE
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
News Preview
Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels
Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
11.11.2024
JNJ
LISTED
NYSE
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
News Preview
The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study
A greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants o...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
08.11.2024
JNJ
LISTED
NYSE
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
News Preview
If approved, DARZALEX FASPRO® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage
RARITAN, N.J., Nov. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) t...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
JNJ
LISTED
NYSE
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
News Preview
New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions and a plenary session
Results from the Phase 2 DAHLIAS study of nipocalimab in SjD show nipocalimab met the primary endpoint with a reduction in Cli...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2024
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
News Preview
A greater number of patients treated with subcutaneous TREMFYA® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo
TREMFYA® could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (C...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2024
JNJ
LISTED
NYSE
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
News Preview
First-of-its-kind Phase 3b study shows TREMFYA® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement
Johnson & Johnson launches library of clinical images from Phase 3b VISIBLE study to enhance clinical decision making for people across all skin tones liv...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
JNJ
LISTED
NYSE
Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress
News Preview
New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to two or more oral antidepressants (treatment-resistant depression)
23 abstracts highlight data from Company's robust portfolio and pipeline, including clinical insights on major depressive disorder and the significan...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2024
JNJ
LISTED
NYSE
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
News Preview
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied
SAVANNAH, Ga., Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipo...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
JNJ
LISTED
NYSE
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company’s common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024....
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
JNJ
LISTED
NYSE
Johnson & Johnson Reports Q3 2024 Results
News Preview
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer. “During the quarter, we advanced ou...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
10.10.2024
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will participate in the Stifel 2024 Healthcare Conference on Monday, November 18th, at the Lotte New York Palace in New York. Michael Bodner, Group President, Heart Recovery & Circulatory Restoration, will represent the Company in a session scheduled at 10:55 a.m. (Eastern Time).
This live audio webcast will...
Themefolio
Profiler
Peergroup
© PR Newswire
10.10.2024
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
News Preview
TREMFYA® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease
TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory
Ninety percent more biologic-naïve patients and...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2024
JNJ
LISTED
NYSE
Johnson & Johnson Completes Acquisition of V-Wave
News Preview
Johnson & Johnson1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech.
The acquisition of V-Wave extends Johnson & Johnson MedTech’...
Themefolio
Profiler
Peergroup
© BusinessWire
04.10.2024
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12th, at the InterContinental Boston in Boston, MA. Biljana Naumovic, President, Solid Tumor, U.S. Oncology and Mark Wildgust, Vice President, Global Medical Affairs Oncology, will represent the Company in a session scheduled at 1...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
JNJ
LISTED
NYSE
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
News Preview
Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA® reduced risk of death by 23 percent at 24 months compared to enzalutamide
LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA® (apalutamide) provided a...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
JNJ
LISTED
NYSE
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
News Preview
Results from CEPHEUS study highlight DARZALEX FASPRO® quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility
New indication would be the first FDA-approved treatment regimen for newly diagnosed multiple myeloma based on a study with MRD-negativity as the primary endpoint
RARITAN, N.J.,...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
JNJ
LISTED
NYSE
Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
News Preview
The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3 †.
93% of patients become free from glasses at all distances.#4 ‡
TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes.5¶
JACKSONVILLE, Fl...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
JNJ
LISTED
NYSE
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
News Preview
45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study
Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today long-term results from...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
JNJ
LISTED
NYSE
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
News Preview
Minimal residual disease (MRD)-negativity rate of 10-5 more than doubled by 12 months with DARZALEX FASPRO® in maintenance therapy compared to lenalidomide alone, resulting in improvement in 30-month progression-free survival
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from three studies...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
JNJ
LISTED
NYSE
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
News Preview
Study of the first and only subcutaneous quadruplet regimen demonstrates 60.9 percent improvement in minimal residual disease (MRD)-negativity and 43 percent reduction in the risk of progression or death
Phase 3 CEPHEUS study results presented in late-breaking oral presentation at the International Myeloma Society (IMS) Annual Meeting
RIO DE JAN...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
JNJ
LISTED
NYSE
Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disea
News Preview
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY® and TECVAYLI® monotherapies
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever bispecific antibody...
Themefolio
Profiler
Peergroup
© PR Newswire
27.09.2024
JNJ
LISTED
NYSE
TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
News Preview
Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody
Safety profile, including infection rates, similar to TALVEY® and DARZALEX FASPRO® monotherapies
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Joh...
Themefolio
Profiler
Peergroup
© BusinessWire
21.09.2024
JNJ
LISTED
NYSE
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
News Preview
Attorneys representing tens of thousands of women with ovarian cancer linked to use of Johnson & Johnson (NYSE:JNJ) talc products say they will immediately seek dismissal of a pre-packaged bankruptcy that the company filed earlier today in Texas.
In its filing, the New Jersey-based pharmaceutical giant claims that approximately 83% of those p...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2024
JNJ
LISTED
NYSE
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
News Preview
Johnson & Johnson (NYSE: JNJ) (the “Company”) announced that its subsidiary, Red River Talc LLC (“Red River”), filed a voluntary prepackaged Chapter 11 bankruptcy case today in the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) to fully and finally resolve all current and future claims related to ovarian canc...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2024
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
News Preview
Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT® this year, with four indications overall
RARITAN, N.J., Sept. 19, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantama...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
JNJ
LISTED
NYSE
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
News Preview
TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence
BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatme...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2024
JNJ
LISTED
NYSE
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
News Preview
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive
BARCELONA, Spain, Sept. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1...
Themefolio
Profiler
Peergroup
© PR Newswire
14.09.2024
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
News Preview
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease
New results show potential of RYBREVANT® beyond lung cancer
BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivant...
Themefolio
Profiler
Peergroup
© PR Newswire
14.09.2024
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
News Preview
Post-progression outcomes showed significant and sustained improvement for RYBREVANT® plus standard of care versus chemotherapy alone
BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy led...
Themefolio
Profiler
Peergroup
© PR Newswire
12.09.2024
JNJ
LISTED
NYSE
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
News Preview
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5
TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis
HORSHAM,...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2024
JNJ
LISTED
NYSE
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
News Preview
Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT®, a three-fold reduction from 67.4 percent historically seen with standard IRR management
SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the open-label Phase 2 SKIPPirr study, which ev...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2024
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
News Preview
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy as first-line therapy
Results from an interim analysis featured in late-breaker oral presentation at WCLC
SAN DIEGO, Sept. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2024
JNJ
LISTED
NYSE
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
News Preview
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host t...
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2024
JNJ
LISTED
NYSE
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
News Preview
Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies
Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
JNJ
LISTED
NYSE
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
News Preview
Four RYBREVANT® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers
New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer
RARITAN, N.J., Aug. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company's i...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2024
JNJ
LISTED
NYSE
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
News Preview
Johnson & Johnson (NYSE: JNJ) today announced that Dr. Peter M. Fasolo will retire from his position as Executive Vice President, Chief Human Resources Officer at the end of this year, following 16 years of leadership and service to the Company. Throughout his distinguished career, Dr. Fasolo has worked with the organization’s Board of Directo...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2024
JNJ
LISTED
NYSE
Johnson & Johnson to Acquire V-Wave
News Preview
Johnson & Johnson1 (NYSE: JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, s...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2024
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
News Preview
RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib
Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-long...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2024
JNJ
LISTED
NYSE
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
News Preview
Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks
Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of real-world use that reinforce the safety and efficacy of SPRAVATO®
TITUSVILLE, N.J., July 22, 2024 /PRN...
Themefolio
Profiler
Peergroup
© PR Newswire
03.07.2024
JNJ
LISTED
NYSE
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
News Preview
Phase 3 PAPILLON study showed RYBREVANT® in combination with carboplatin and pemetrexed significantly improved progression-free survival, reducing the risk of disease progression or death by 60 per cent versus carboplatin and pemetrexed alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations.1
TORONTO, July 3, 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
02.07.2024
JNJ
LISTED
NYSE
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
News Preview
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy
RARITAN, N.J., July 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2024
JNJ
LISTED
NYSE
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
News Preview
First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+
HELSINKI, June 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the nipocalimab P...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
